Corbus Pharmaceuticals (CRBP) Corporate presentation summary

Portfolio and resources

• Pipeline centers on CRB-701, a Nectin-4 ADC for OPSCC and cervical cancer, and CRB-913, a peripherally restricted CB1 inverse agonist for obesity.

• Cash, cash equivalents and investments totaled $118M as of June 30, 2026; 18.7M common shares issued and outstanding, or ~22.4M fully diluted.

CRB-701 oncology

• In OPSCC, CRB-701 achieved 42.9% confirmed ORR at 3.6 mg/kg Q3W (9/21), 85.7% DCR, 6.3-month DoR and 5.6-month PFS; 8/9 HPV+ responders.

• In cervical cancer, 3.6 mg/kg produced 34.4% ORR, 75.0% DCR, 8.0-month DoR and 4.3-month PFS; results are from the ASCO April 1, 2026 data cut.

• Across the 317-patient safety population, treatment-related AEs were 12.6% Grade 3 and 0.3% Grade 4; AE discontinuations were 2.8%, including 1.9% due to ocular AEs.

• TEMPO-1 is a randomized registrational study in recurrent OPSCC after platinum and anti-PD-(L)1 therapy, comparing CRB-701 3.6 mg/kg with investigator’s choice; primary endpoints are ORR and OS.

• Milestones include 1L OPSCC CRB-701 plus pembrolizumab data in Q1 2027, interim 2L OPSCC ORR in 1H 2028 and potential BLA filing in 2H 2028.

CRB-913 obesity

• In the 254-patient, 12-week CANYON-1 study, 60 mg achieved 5.0% placebo-adjusted weight loss; weight loss was dose-dependent, continued without plateauing, and all 60 mg completers lost weight.

• At 60 mg, 12.9% discontinued treatment due to AEs; no serious treatment-related AEs occurred across CRB-913 dose groups.

• Psychiatric AEs were mostly mild or moderate and transient; GI AEs were mild or moderate, with no severe or serious GI events.

• Planned next steps include presenting CANYON-1 data at ObesityWeek in November 2026, engaging with FDA and starting the CANYON-2 Phase 2 monotherapy study in 1H 2027.

• CRB-913 comparisons with oral GLP-1 drugs are cross-trial observations from separate clinical settings, not head-to-head studies.